Johnson & Johnson (JNJ) tops revenue estimates, reiterates forecast

Johnson & Johnson's (NYSE: JNJ) reported today fourth-quarter results that exceeded analyst expectations.

Adjusted earnings per share (EPS) came in at $2.29, slightly surpassing the average analyst estimate of $2.28. The company also reported sales of $21.40 billion for the quarter, beating the estimated $21.00 billion.

Looking ahead, Johnson & Johnson maintained its annual forecast, expecting adjusted operating EPS in the range of $10.55 to $10.75.

The company also reiterated its full-year guidance for 2024, anticipating operational sales growth between 5% and 6%.

“Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer.

“We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.”

Shares fell 0.5% in early Tuesday trade.

By Senad Karaahmetovic

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• MIND Technology (MIND) Misses Q1 EPS by 5c